Ï㽶ÊÓƵ

In December 2020, Utah’s Newborn Screening Program identified the first patient with Guanidinoacetate methyltransferase (GAMT) deficiency solely through newborn screening. GAMT deficiency is an inherited condition that affects the body’s...

Ï㽶ÊÓƵ of Utah Health vaccinated its first round of frontline health care staff after receiving the Pfizer-BioNTech COVID-19 vaccine just hours earlier. A registered nurse in the medical intensive care...

Highlighting investigators and their pioneering research programs, the Vitae program seeds new collaborations and development strategies by humanizing research through story.

Massive "plumes" of a key neurotransmitter surging in the brain could help explain the onset of migraine with aura—and potentially a broad swath of neurologic disease, including stroke and traumatic...

Researchers at the Ï㽶ÊÓƵ of Utah Health have identified a new therapeutic target to treat patients with type 1 diabetes.

Samuel R.G. Finlayson, MD, MPH, MBA has been appointed Associate Vice President (AVP) for Clinical Affairs and Chief Clinical Officer for Ï㽶ÊÓƵ of Utah Health (U of U Health). The...

In anticipation of Emergency Use Authorization by the Food and Drug Administration, Ï㽶ÊÓƵ of Utah Health is prepared to properly store and distribute COVID-19 vaccines. A vaccine is a first...

Sobering new statistics released by the Global Burden of Disease study found no significant reduction in the number of people with treatable sight loss worldwide since 2010 as public health...